Sign up to save your podcasts
Or
Share Understanding ROS1-positive Lung Cancer with Dr. Alice Shaw
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Understanding ROS1-positive Lung Cancer with Dr. Alice Shaw
In this episode of Living With Lung Cancer: Ask Me Anything, host Annabelle Gurwitch sits down with Dr. Alice Shaw from Dana-Farber Cancer Institute for an in-depth conversation about ROS1-positive lung cancer. Learn about this rare biomarker affecting only 1-2% of lung cancer patients, breakthrough targeted therapies, and how next-generation treatments are transforming outcomes.
Dr. Shaw, an internationally recognized expert in targeted therapies, discusses the importance of biomarker testing, clinical trial participation, and why specialized care matters for rare biomarkers. She explains how next-generation ROS1 inhibitors are more potent, selective, and designed to penetrate the brain—addressing one of lung cancer's most challenging complications.
Whether you're newly diagnosed with ROS1-positive lung cancer, a caregiver, or seeking to understand treatment advances, this episode provides essential information and real hope through scientific advancement.
Topics covered:
• What "oncogene-driven" lung cancer means and why it's good news
• The critical importance of comprehensive biomarker testing
• Tissue vs. liquid biopsy: which test and when
• How ROS1 targeted therapies have evolved over 15 years
• Next-generation treatments with better efficacy and fewer side effects
• Brain penetration and preventing metastases
• How to participate in clinical trials while keeping your local care team
• Advocating for specialized care and second opinions
• Resources for ROS1 patients and caregivers
Guest: Dr. Alice Shaw, Director of the Center for Thoracic Cancers at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School
Host: Annabelle Gurwitch, New York Times bestselling author, LCFA Speakers Bureau member, and lung cancer survivor
Show Notes - https://lcfamerica.org/wp-content/uploads/2025/11/AMA-ROS1-Positive-Lung-Cancer-Show-Notes.pdf
Transcript - https://lcfamerica.org/wp-content/uploads/2025/11/AMA-ROS1-Treatments-w-Dr-Alice-Shaw-Transcript.pdf
Watch Video - https://youtu.be/uy0B67AyyVs
View all episodes
By Lung Cancer Foundation of AmericaIn this episode of Living With Lung Cancer: Ask Me Anything, host Annabelle Gurwitch sits down with Dr. Alice Shaw from Dana-Farber Cancer Institute for an in-depth conversation about ROS1-positive lung cancer. Learn about this rare biomarker affecting only 1-2% of lung cancer patients, breakthrough targeted therapies, and how next-generation treatments are transforming outcomes.
Dr. Shaw, an internationally recognized expert in targeted therapies, discusses the importance of biomarker testing, clinical trial participation, and why specialized care matters for rare biomarkers. She explains how next-generation ROS1 inhibitors are more potent, selective, and designed to penetrate the brain—addressing one of lung cancer's most challenging complications.
Whether you're newly diagnosed with ROS1-positive lung cancer, a caregiver, or seeking to understand treatment advances, this episode provides essential information and real hope through scientific advancement.
Topics covered:
• What "oncogene-driven" lung cancer means and why it's good news
• The critical importance of comprehensive biomarker testing
• Tissue vs. liquid biopsy: which test and when
• How ROS1 targeted therapies have evolved over 15 years
• Next-generation treatments with better efficacy and fewer side effects
• Brain penetration and preventing metastases
• How to participate in clinical trials while keeping your local care team
• Advocating for specialized care and second opinions
• Resources for ROS1 patients and caregivers
Guest: Dr. Alice Shaw, Director of the Center for Thoracic Cancers at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School
Host: Annabelle Gurwitch, New York Times bestselling author, LCFA Speakers Bureau member, and lung cancer survivor
Show Notes - https://lcfamerica.org/wp-content/uploads/2025/11/AMA-ROS1-Positive-Lung-Cancer-Show-Notes.pdf
Transcript - https://lcfamerica.org/wp-content/uploads/2025/11/AMA-ROS1-Treatments-w-Dr-Alice-Shaw-Transcript.pdf
Watch Video - https://youtu.be/uy0B67AyyVs